<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01406145</url>
  </required_header>
  <id_info>
    <org_study_id>0777-CL-0030</org_study_id>
    <nct_id>NCT01406145</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and Tolerability of ASP0777 in Subjects With Alzheimer's Disease (AD) Taking a Stable Dose of Donepezil</brief_title>
  <official_title>A Phase 1b, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Sequential Dose Study of the Safety and Tolerability of ASP0777 in Subjects With Alzheimer's Disease on Donepezil</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is intended to determine the safety and tolerability of ASP0777 in subjects with
      Alzheimer's Disease (AD) taking a stable dose of donepezil.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 16, 2011</start_date>
  <completion_date type="Actual">November 4, 2011</completion_date>
  <primary_completion_date type="Actual">November 4, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and percentage of subjects with adverse events</measure>
    <time_frame>Up to 56 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic assessment of AUC, maximum concentration (Cmax), minimum concentration (Cmin) and time to maximum concentration (tmax) through analysis of blood samples</measure>
    <time_frame>Up to 56 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>ASP0777 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASP0777 low dose for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASP0777 low dose, then high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASP0777 low dose for 1 week and ASP0777 high dose for 5 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASP0777 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASP0777 high dose for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP0777</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>ASP0777 high dose</arm_group_label>
    <arm_group_label>ASP0777 low dose</arm_group_label>
    <arm_group_label>ASP0777 low dose, then high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has a Mini-Mental Status Exam score of 18-26

          -  Subject has a diagnosis of &quot;probable&quot; Alzheimer's Disease

          -  Subject has used donepezil for at least 3 months and has been on a stable dose for at
             least 6 weeks prior to screening

          -  Subject has a reliable adult who is residing with him/her during the outpatient
             portion of the study

          -  Subject is medically stable

          -  Subject has adequate cognitive, hearing, vision, and language skills

          -  Subject is able to ingest oral tablets

        Exclusion Criteria:

          -  Subject has received any investigational product in another clinical study or
             post-marketing clinical study within past 3 months

          -  Subject has any clinically significant abnormal laboratory tests

          -  Subject is a female who is pregnant, lactating or of childbearing potential who
             refuses to use a form of contraception during the study

          -  Subject has a history of a drug allergy or intolerance to memantine or a related
             compound

          -  Subject is currently using anti-dementia drugs (except for donepezil) or has used any
             such drugs within the last 4 weeks

          -  Subject has a score of 2 on item 16 of Cornell Scale for Depression in Dementia (CSDD)
             or has an overall CSDD score &gt; 10

          -  Subject is using off-label medicines, non-medicinal compounds, or dietary aids/food
             supplements to improve cognition that have not been at a stable dose for at least 4
             weeks prior to Screening and/or are anticipated to change dosing regimen during the
             study

          -  Subject has a history of drug or alcohol abuse within the past 12 months or subject
             consumes &gt; 1 drink of alcohol daily, or is unable to refrain from alcohol during the
             study

          -  Subject is a current smoker or recently quit smoking (within the past 12 months)

          -  Subject has a clinically significant medical condition that is unstable or is likely
             to become unstable during the course of the study

          -  Subject has history of seizures, other than febrile seizures during infancy

          -  Subject has history of repeated falls within past 6 months

          -  Subject has a major psychiatric illness or has received treatment for symptoms of a
             major psychiatric illness within past 1 year. Mild psychiatric disorders are allowable
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pacific Research Network, Inc.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Clinical</name>
      <address>
        <city>Hallandale Beach</city>
        <state>Florida</state>
        <zip>33009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://astellasclinicalstudyresults.com/study.aspx?ID=296</url>
    <description>Link to results on the Astellas Clinical Study Results website</description>
  </link>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>July 6, 2011</study_first_submitted>
  <study_first_submitted_qc>July 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2011</study_first_posted>
  <last_update_submitted>January 28, 2019</last_update_submitted>
  <last_update_submitted_qc>January 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ASP0777</keyword>
  <keyword>Alzheimer's Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Access to anonymized individual participant level data collected during the trial, in addition to study-related supporting documentation, is planned for trials conducted with approved product indications and formulations, as well as compounds terminated during development. Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.</ipd_time_frame>
    <ipd_access_criteria>Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.</ipd_access_criteria>
    <ipd_url>https://www.clinicalstudydatarequest.com/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

